Objective:
To seek approval for Arexvy, a vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older in China.
Key Findings:
- Arexvy aims to protect adults aged 60 and older from RSV, which affects over six million in China annually.
- The vaccine has shown positive phase 3 trial results and an acceptable safety profile.
- Arexvy is already approved in over 65 countries for adults aged 60 and older.
Interpretation:
If approved, Arexvy would be the first RSV vaccine available in China for older adults, addressing a significant public health need.
Limitations:
- A protective immune response may not be achieved in all vaccinees.
- The regulatory decision is not expected until 2027.
Conclusion:
Arexvy represents a potential advancement in RSV prevention for older adults in China, with significant implications for public health.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
